$NKTR I do not agree with the notion that in case of rejection of 181 as a new drug would cut this stock in half. Other pipelines using Bempeg for various cancer treatments would be worth 10 billion range (minimum) that is about 3 times current market cap. Just my opinion. Could be incorrect, of course.
  • 5
  • 10